NetworkNewsBreaks – Pressure BioSciences Inc. (P
Post# of 1354
(Total Views: 213)
Posted On: 05/04/2022 3:11:13 PM
NetworkNewsBreaks – Pressure BioSciences Inc. (PBIO) Enters First UST Early Access Manufacturing Agreement
Pressure BioSciences (OTCQB: PBIO), a leader in the development and sale of innovative, broadly enabling, pressure-based instruments, consumables, and specialty services to the worldwide biopharmaceuticals, cosmetics, nutraceuticals, agrochem, and food & beverage industries, has signed its inaugural nanoemulsions development and manufacturing agreement under its recently released Ultra Shear Technology(TM) (“UST”) early-access program. The agreement, signed with Safer Medical of Montana (“SMM”), covers formulation, pilot batches and commercial production for a CBD topical spray designed to reduce pain. According to the announcement, all products discussed in the contract will include high-quality nanoemulsions of oils in water produced by using PBI’s revolutionary UST platform. The final formulation development is expected to be complete before May 31, 2022, with two pilot manufacturing runs slated for June and production for commercial sale scheduled to start in Q3 2022. “It is an exciting challenge to have customers pushing us to move faster into the launch of our UST processing services,” said Pressure BioSciences chair Jeffrey N. Peterson in the press release. “We’ve been completing ‘proof of concept’ runs for a number of companies in different markets, and each of them has been amazed by the product improvements resulting from UST processing. Along the way, we have learned a great deal about how to optimize the potential of the nanoemulsion-creation process performed within the UST platform, which has resulted in additional patent filings. One of the primary goals enabled and achieved by UST is to minimize the need for artificial and/or undesirable chemical additives that are routinely used by many current manufacturers to create and stabilize existing emulsion products at the macro, micro and nano scales. As consumers begin to experience the clear benefits of these newly created UST nanoemulsion products, we eagerly anticipate the tectonic shifts in market expectations and dynamics that we and our partners are confident will ensue.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Pressure BioSciences (OTCQB: PBIO), a leader in the development and sale of innovative, broadly enabling, pressure-based instruments, consumables, and specialty services to the worldwide biopharmaceuticals, cosmetics, nutraceuticals, agrochem, and food & beverage industries, has signed its inaugural nanoemulsions development and manufacturing agreement under its recently released Ultra Shear Technology(TM) (“UST”) early-access program. The agreement, signed with Safer Medical of Montana (“SMM”), covers formulation, pilot batches and commercial production for a CBD topical spray designed to reduce pain. According to the announcement, all products discussed in the contract will include high-quality nanoemulsions of oils in water produced by using PBI’s revolutionary UST platform. The final formulation development is expected to be complete before May 31, 2022, with two pilot manufacturing runs slated for June and production for commercial sale scheduled to start in Q3 2022. “It is an exciting challenge to have customers pushing us to move faster into the launch of our UST processing services,” said Pressure BioSciences chair Jeffrey N. Peterson in the press release. “We’ve been completing ‘proof of concept’ runs for a number of companies in different markets, and each of them has been amazed by the product improvements resulting from UST processing. Along the way, we have learned a great deal about how to optimize the potential of the nanoemulsion-creation process performed within the UST platform, which has resulted in additional patent filings. One of the primary goals enabled and achieved by UST is to minimize the need for artificial and/or undesirable chemical additives that are routinely used by many current manufacturers to create and stabilize existing emulsion products at the macro, micro and nano scales. As consumers begin to experience the clear benefits of these newly created UST nanoemulsion products, we eagerly anticipate the tectonic shifts in market expectations and dynamics that we and our partners are confident will ensue.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Pressure Biosciences (PBIO) Stock Research Links
Scroll down for more posts ▼